Brief: Paion Grants Exclusive License To TTY Biopharm
05/03/2021 08:04
March 5 (Reuters) - PAION AG PA8G.DE :
* GRANTS EXCLUSIVE LICENSE TO TTY BIOPHARM FOR DEVELOPMENT
AND
COMMERCIALIZATION OF REMIMAZOLAM IN TAIWAN
* EUR 1.1 MILLION UPFRONT PAYMENT TO PAION
* SUPPLY OF DRUG PRODUCT AT A PERCENTAGE OF NET SELLING
PRICE
Source text for Eikon: ID:nEQ9VWQpJa
Further company coverage: PA8G.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 6600;))
Recent news on PAION AG
See all newsBrief: Paion AG To Issue Approx 4.8 Mln Shares In Capital Increase With Subscription Rights
Brief: Paion AG Reports Developments On Commercial Activities In Europe
Brief: Paion Q1 EBITDA Up At EUR 15 Mln
Brief: Paion Grants Exclusive License To Cristália For Development And Commercialization Of Remimazolam In Latin America
Brief: Paion Announces Sebastian Werner As New CFO, Effective 1 June 2022